

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 10, 2025

Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647

RRID:AB_2535862

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# A-21445, RRID:AB_2535862)

Antibody Information

URL: http://antibodyregistry.org/AB_2535862

Proper Citation: (Thermo Fisher Scientific Cat# A-21445, RRID:AB_2535862)

Target Antigen: Human IgG (H+L)

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: ICC/IF (1-10 µg/mL), IHC (1-10 µg/mL), WB (1:2,000)

Antibody Name: Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647

Description: This polyclonal secondary targets Human IgG (H+L)

Target Organism: human

Defining Citation: [PMID:24081977](https://pubmed.ncbi.nlm.nih.gov/24081977/), [PMID:22553322](https://pubmed.ncbi.nlm.nih.gov/22553322/), [PMID:22734046](https://pubmed.ncbi.nlm.nih.gov/22734046/), [PMID:19542447](https://pubmed.ncbi.nlm.nih.gov/19542447/), [PMID:21693586](https://pubmed.ncbi.nlm.nih.gov/21693586/), [PMID:21224470](https://pubmed.ncbi.nlm.nih.gov/21224470/), [PMID:19704008](https://pubmed.ncbi.nlm.nih.gov/19704008/), [PMID:22090361](https://pubmed.ncbi.nlm.nih.gov/22090361/), [PMID:20194765](https://pubmed.ncbi.nlm.nih.gov/20194765/), [PMID:20008521](https://pubmed.ncbi.nlm.nih.gov/20008521/), [PMID:20606164](https://pubmed.ncbi.nlm.nih.gov/20606164/), [PMID:23637402](https://pubmed.ncbi.nlm.nih.gov/23637402/)

Antibody ID: AB_2535862

Vendor: Thermo Fisher Scientific

Catalog Number: A-21445

Record Creation Time: 20241130T060505+0000

Record Last Update: 20241130T061735+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647.

Warning: Discontinued at Molecular Probes
Applications: ICC/IF (1-10 µg/mL), IHC (1-10 µg/mL), WB (1:2,000)

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 79 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. *Cell*, 187(9), 2305.

Peel JN, et al. (2024) Neutralizing IFN-? autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals. *The Journal of clinical investigation*, 134(8).

Hsu J, et al. (2024) Protocol for iterative indirect immunofluorescence imaging in cultured cells, tissue sections, and metaphase chromosome spreads. *STAR protocols*, 5(3), 103190.

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell*, 187(2), 390.

Fernández I, et al. (2024) Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus. *Cell*, 187(16), 4246.

Mihalas BP, et al. (2024) Age-dependent loss of cohesion protection in human oocytes. *Current biology : CB*, 34(1), 117.

Slein MD, et al. (2024) Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D. *Cell reports. Medicine*, 5(2), 101417.

Takaki T, et al. (2024) Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING. *Molecular cell*, 84(11), 2203.

Pai C, et al. (2024) Loss of Baz1b in mice causes perinatal lethality, growth failure, and variable multi-system outcomes. *Developmental biology*, 505, 42.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Karakus U, et al. (2024) H19 influenza A virus exhibits species-specific MHC class II receptor usage. *Cell host & microbe*, 32(7), 1089.

Fert A, et al. (2024) Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies. *iScience*, 27(9), 110670.

Rosain J, et al. (2024) Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases. *The Journal of experimental medicine*, 221(11).

Post Y, et al. (2023) Novel Frizzled-specific antibody-based Wnt mimetics and Wnt superagonists selectively activate WNT/ β -catenin signaling in target tissues. *Cell chemical biology*, 30(8), 976.

Le Voyer T, et al. (2023) Autoantibodies against type I IFNs in humans with alternative NF- κ B pathway deficiency. *Nature*, 623(7988), 803.

Pai C, et al. (2023) Sequencing Reveals miRNAs Enriched in the Developing Mouse Enteric Nervous System. *Non-coding RNA*, 10(1).

Chen Y, et al. (2023) Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. *iScience*, 26(1), 105783.

Kschonsak YT, et al. (2023) Potent and selective binders of the E3 ubiquitin ligase ZNRF3 stimulate Wnt signaling and intestinal organoid growth. *Cell chemical biology*.

Cognasse F, et al. (2023) Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. *EBioMedicine*, 87, 104414.

Hoffmann MAG, et al. (2023) ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. *Cell*, 186(11), 2380.